BACKGROUND: Reliable reporting of chemotherapy-induced neurotoxicity is important. The objectives of the current study were to evaluate the differences in the peripheral neurotoxicity sections of several widely used chemotherapy-related toxicity grading systems, and the differences in the way in which observers interpret these scales. PATIENTS AND METHODS: Two neurologists independently rated the severity of chemotherapy-induced peripheral neuropathy, according to WHO, ECOG, Ajani, and NCIC-CTC criteria in 37 patients. RESULTS: The highest percentage grade 1, grade 2 and grade 3 peripheral neurotoxicity was noted when employing the WHO, Ajani and NCIC-CTC scales, respectively. Percentage inter-observer agreement across all grades of severity ranged from 45.9 (NCIC-CTC) to 83.8 (WHO). The degree of agreement varied from 'poor to fair' to 'substantial'. Percentage inter-observer agreement for the dichotomy grade < or = 2 and grade 3 ranged from 81.1 (NCIC-CTC) to 94.6 (Ajani and WHO), however, exact agreement on grade 3 peripheral neurotoxicity ranged from 0 (Ajani and WHO) to 42% (NCIC-CTC). Percentage interscale agreement for the dichotomy grade < or = 2 and grade 3 varied from 67.6 (WHO and NCIC-CTC) to 100 (WHO and ECOG). Interobserver disagreement of severity grading was partly due to different interpretation of scale parameters. CONCLUSIONS: Our results suggest that caution should be used in interpreting results across studies using different scales for neurotoxicity grading in chemotherapy-related peripheral neuropathy. When (multicentre) trials are to be undertaken with potential neurotoxic or neuroprotective agents, consensus should be sought regarding the toxicity rating scale used, and its interpretation by participating physicians.
BACKGROUND: Reliable reporting of chemotherapy-induced neurotoxicity is important. The objectives of the current study were to evaluate the differences in the peripheral neurotoxicity sections of several widely used chemotherapy-related toxicity grading systems, and the differences in the way in which observers interpret these scales. PATIENTS AND METHODS: Two neurologists independently rated the severity of chemotherapy-induced peripheral neuropathy, according to WHO, ECOG, Ajani, and NCIC-CTC criteria in 37 patients. RESULTS: The highest percentage grade 1, grade 2 and grade 3 peripheral neurotoxicity was noted when employing the WHO, Ajani and NCIC-CTC scales, respectively. Percentage inter-observer agreement across all grades of severity ranged from 45.9 (NCIC-CTC) to 83.8 (WHO). The degree of agreement varied from 'poor to fair' to 'substantial'. Percentage inter-observer agreement for the dichotomy grade < or = 2 and grade 3 ranged from 81.1 (NCIC-CTC) to 94.6 (Ajani and WHO), however, exact agreement on grade 3 peripheral neurotoxicity ranged from 0 (Ajani and WHO) to 42% (NCIC-CTC). Percentage interscale agreement for the dichotomy grade < or = 2 and grade 3 varied from 67.6 (WHO and NCIC-CTC) to 100 (WHO and ECOG). Interobserver disagreement of severity grading was partly due to different interpretation of scale parameters. CONCLUSIONS: Our results suggest that caution should be used in interpreting results across studies using different scales for neurotoxicity grading in chemotherapy-related peripheral neuropathy. When (multicentre) trials are to be undertaken with potential neurotoxic or neuroprotective agents, consensus should be sought regarding the toxicity rating scale used, and its interpretation by participating physicians.
Authors: Ellen M Lavoie Smith; Clare Kuisell; Grace A Kanzawa-Lee; Celia M Bridges; Paola Alberti; Guido Cavaletti; Rima Saad; Susanna Park Journal: Lancet Haematol Date: 2020-05 Impact factor: 18.959
Authors: Jennifer Le-Rademacher; Rahul Kanwar; Drew Seisler; Deirdre R Pachman; Rui Qin; Alexej Abyzov; Kathryn J Ruddy; Michaela S Banck; Ellen M Lavoie Smith; Susan G Dorsey; Neil K Aaronson; Jeff Sloan; Charles L Loprinzi; Andreas S Beutler Journal: Support Care Cancer Date: 2017-06-20 Impact factor: 3.603
Authors: Barbara K Bennett; Susanna B Park; Cindy S-Y Lin; Michael L Friedlander; Matthew C Kiernan; David Goldstein Journal: Support Care Cancer Date: 2012-03-17 Impact factor: 3.603
Authors: Kathleen A Griffith; Susan G Dorsey; Cynthia L Renn; Shijun Zhu; Mary E Johantgen; David R Cornblath; Andreas A Argyriou; Guido Cavaletti; Ingemar S J Merkies; Paola Alberti; Tjeerd J Postma; Emanuela Rossi; Barbara Frigeni; Jordi Bruna; Roser Velasco; Haralabos P Kalofonos; Dimitri Psimaras; Damien Ricard; Andrea Pace; Edvina Galie; Chiara Briani; Chiara Dalla Torre; Catharina G Faber; Roy I Lalisang; Willem Boogerd; Dieta Brandsma; Susanne Koeppen; Joerg Hense; Dawn J Storey; Simon Kerrigan; Angelo Schenone; Sabrina Fabbri; Maria Grazia Valsecchi Journal: J Peripher Nerv Syst Date: 2014-06 Impact factor: 3.494
Authors: Gary R Zirpoli; Susan E McCann; Lara E Sucheston-Campbell; Dawn L Hershman; Gregory Ciupak; Warren Davis; Joseph M Unger; Halle C F Moore; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; G Thomas Budd; Kathy S Albain; Christine B Ambrosone Journal: J Natl Cancer Inst Date: 2017-12-01 Impact factor: 13.506